HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy.

AbstractPURPOSE:
Thoughtful integration of surgical and medical approaches to metastatic renal cell carcinoma is paramount for maximizing disease control. Accomplishing this in the current era of targeted molecular therapies presents unique challenges and opportunities.
MATERIALS AND METHODS:
A systematic review of the MEDLINE and PubMed databases, and relevant urological and oncological journals was performed pertaining to cytoreductive nephrectomy, metastasectomy, targeted molecular therapies for renal cell carcinoma, and neoadjuvant and adjuvant approaches to the management of advanced renal cell carcinoma.
RESULTS:
Cytoreductive nephrectomy provides an overall survival advantage in select patients with metastatic renal cell carcinoma who receive subsequent interferon-alpha. However, cytokine therapies are now being supplanted by targeted molecular approaches that block the effects of vascular endothelial growth factor and other molecular events. Although cytoreductive nephrectomy remains a standard of care, limited insight into the biological effects of nephrectomy on mechanisms such as immunoregulation and angiogenesis precludes definitive statements about how to integrate surgery and targeted agents. Ongoing investigation involving basic science and translational research is required to optimize the integration of these approaches. Adjuvant and neoadjuvant vascular endothelial growth factor targeted approaches to renal cell carcinoma are now also being explored and the unique side effects of these agents, including potential effects on wound healing and vascular integrity, require careful consideration.
CONCLUSIONS:
Integrated approaches involving surgery and vascular endothelial growth factor targeted therapies hold much promise for the management of advanced renal cell carcinoma. Prospective clinical testing with vigilant attention to the risk-benefit ratio and thoughtful evaluation of biological correlates are required to optimize these approaches.
AuthorsBrian I Rini, Steven C Campbell
JournalThe Journal of urology (J Urol) Vol. 177 Issue 6 Pg. 1978-84 (Jun 2007) ISSN: 0022-5347 [Print] United States
PMID17509276 (Publication Type: Journal Article, Review)
Chemical References
  • Antineoplastic Agents
  • Interferons
  • Receptors, Vascular Endothelial Growth Factor
Topics
  • Antineoplastic Agents (therapeutic use)
  • Carcinoma, Renal Cell (secondary, therapy)
  • Combined Modality Therapy
  • Humans
  • Interferons (therapeutic use)
  • Kidney Neoplasms (pathology, therapy)
  • Nephrectomy
  • Receptors, Vascular Endothelial Growth Factor (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: